SBIR/STTR Research Award

Functional Analogs of Cellular Phosphoinositides

Award identifier a3371cc92f05ccae899ccc700f5a789334ca745af9cb4e3660a545eeecc9461eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,992

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NUTRIMED BIOTECH
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The cellular phosphoinositides, including the phosphatidylinositols and their mono- and polyphosphate derivatives, are critical in intracellular signaling and related cascades. We have developed methods for synthesizing analogs of the cellular series, and the synthetic products are now established as important in vitro reagents. The available synthetic phosphoinositides are not consistently membrane-permeant. Heptakis(acetoxymethyl) derivatives of pbosphatidylinositol-3,4,5-trisphospbate (Ptdlns-3,4,5-P3) enter cells and display activity of Ptdlns-3,4,5-P3. However, polykis-acetoxymethylated phosphoinositides have serious inherent drawbacks as reagents because these suffer extensive phosphate shifts resulting in mixtures of isomers and provide a variable indeterminate amount of the unmodified phosphoinositide inside cells. The overall objective of this investigation is to develop membrane-permeant functional analogs of the phosphoinositides. During Phase I, an approach integrating the design, synthesis and evaluation of novel fonnulations will be tested to assess internalization of synthetic phosphatidylinositol-4,5-bisphosphate (Ptdlns4,5-P2) analogs in cells. During Phase II, the approach will be optimized for Ptdlns-4,5-P2 and extended to a complete range of phosphoinositide analogs. PROPOSED COMMERCIAL APPLICATION: This research will provide a reliable means for introducting quantitatively controlled amounts of exogenous phosphoinositides into intact live cells, and a complete range of novel membrane-permeant phosphoinositide products for use as in vivo research reagents for studies ranging from cell physiology to delivery of phosphoinositide-based therapeutics. These products are in demand but not currently available from any commercial source, and are suitable for transfer directly from production in a laboratory setting to the market.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.